Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-04-25 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Tremelimumab US Priority Review for Imfinzi combo
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement distributed via the RNS service of the London Stock Exchange. The content describes the acceptance of a Biologics License Application (BLA) by the US FDA for a drug combination (tremelimumab and Imfinzi) and provides clinical trial updates (HIMALAYA Phase III results). This is a specific corporate announcement regarding regulatory progress and clinical data, not a full annual report (10-K), an earnings release (ER), or a formal investor presentation (IP). Since it is a formal, time-sensitive announcement distributed through the RNS system that doesn't fit the other specific categories (like DIRS, DIV, or MANG), the most appropriate classification is the general regulatory announcement category, RNS.
2022-04-25 English
ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the FDA granting Priority Review for Enhertu for HER2-mutant NSCLC, including clinical trial results, regulatory status, and company background. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about a drug development and regulatory milestone. The document length is 14,351 characters, indicating it is a substantive report rather than a brief announcement. The Form 6-K is a standard SEC filing for foreign issuers to report material information and is classified under Regulatory Filings (RNS) as it does not fit other specific categories like Annual Report or Earnings Release.
2022-04-19 English
Enhertu granted Priority Review for HER2m NSCLC
Legal Proceedings Report Classification · 99% confidence The document begins with an 'RNS Number' and is dated April 19, 2022, indicating it is a regulatory announcement from the London Stock Exchange's RNS service. The content describes a specific regulatory event: the FDA granting Priority Review for the drug Enhertu for NSCLC. This is a material corporate event announcement, not a full financial report (like 10-K or IR) or a transcript. Since it is a general regulatory announcement disseminated via RNS that doesn't fit perfectly into specific categories like Director's Dealing (DIRS), Dividend (DIV), or Earnings Release (ER), the most appropriate classification is the general regulatory filing category, RNS.
2022-04-19 English
TOTAL VOTING RIGHTS
Major Shareholding Notification Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of 31 March 2022, providing the number of issued shares and voting rights. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, indicating it is a notification about voting rights and capital. The document length is 3158 characters, which is relatively short and primarily serves as an announcement of voting rights information rather than a detailed report or financial statement. This fits the definition of a Major Shareholding Notification (MRQ) as it relates to changes or notifications about significant share ownership or voting rights levels. Therefore, the appropriate classification is MRQ with high confidence.
2022-04-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content details the total number of voting rights and issued share capital as of a specific date (31 March 2022), which is a regulatory disclosure under the Transparency Directive. This type of general regulatory announcement that doesn't fit a more specific category (like DIRS, DIV, or SHA) is best classified as a general Regulatory Filing, which corresponds to the RNS code.
2022-04-01 English
ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains a detailed announcement about the approval of Ondexxya in Japan for FXa inhibitor reversal, including clinical trial data and product information. The document is not an annual or quarterly report, nor is it a transcript, audit report, or management change announcement. It is a regulatory filing providing material information about the company's product approval and related clinical data. The length of the document (9080 characters) and the detailed content confirm it is not merely an announcement of a report but a substantive regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-03-29 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.